MedTrace Logo

NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive Impairment

NCT03482167 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2025-04-04

Study results available
· View outcomes & findings →

Summary

This study will provide insight into whether a nutritional supplement, nicotinamide riboside (NR), improves memory and brain blood flow in older adults with low memory abilities. Overall, this project has the potential to identify a novel, safe and cost-effective strategy for decreasing age-related memory loss.

Conditions

Interventions

DRUG

Niagen®

250 mg capsules (4 capsules daily)

OTHER

Placebo

placebo

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • University of Delaware

    lead OTHER

Principal Investigators

  • Christopher R Martens, Ph.D. · University of Delaware

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-20
Primary Completion
2024-01-08
Completion
2024-01-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03482167 on ClinicalTrials.gov